DDD Related FDA
-
SCOLR Pharma (DDD) Announces Positive Progress for Lead Product
-
SCOLR Pharma (DDD) Announces Positive Ibuprofen Study Results and Status of Commercialization Program
-
SCOLR Pharma (DDD) Announces Positive Results from Its Second 24 Hour CDT-Ondansetron Trial; Discontinues Development of Extended Release Phenylephrine
-
DDD Reports Positive Initial Clinical Results for CDT-Pseudoephedrine
-
DDD Announces the Start of its Extended Release CDT-Pseudoephedrine Human Trials
-
DDD said FDA to permit U.S. testing of its 12-hour ER ibuprofen tablets
Back to DDD Stock Lookup
